.Attribute Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of patients with HER2+ innovative bosom cancer and also energetic or secure brain metastases showed consistent intracranial activity and also wide spread efficiency of T-DXd.